

# Primary Open Angle Glaucoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/PF2EF4EEC999EN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PF2EF4EEC999EN

## Abstracts

**This report can be delivered to the clients within 24 Hours**

DelveInsight's, "Primary Open Angle Glaucoma – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Primary Open Angle Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Primary Open Angle Glaucoma Understanding

#### Primary Open Angle Glaucoma: Overview

Primary open-angle glaucoma is a syndrome of optic nerve damage associated with an open anterior chamber angle and an elevated or sometimes average intraocular pressure (IOP). The most common symptom is the visual field loss. Diagnosis of Primary Open Angle Glaucoma is usually done by ophthalmoscopy, gonioscopy, visual field examination, and measurement of central corneal thickness and IOP. Treatment options includes topical drugs and often requires laser or incisional surgery to increase aqueous drainage.

'Primary Open Angle Glaucoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Wilson's Disease pipeline landscape is provided which includes the disease overview and Primary Open Angle Glaucoma treatment guidelines. The assessment part of the report embraces, in depth Primary Open Angle Glaucoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Open Angle Glaucoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Primary Open Angle Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve Primary Open Angle Glaucoma.

## Primary Open Angle Glaucoma Emerging Drugs Chapters

This segment of the Primary Open Angle Glaucoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Primary Open Angle Glaucoma Emerging Drugs

### PRO-122: Laboratorios Sophia S.A de C.V.

PRO-122 a novel Alpha 2 adrenergic receptor agonists being developed as an ophthalmic solution and is being studied in phase III for the development of primary open glaucoma by Laboratorios Sophia S.A de C.V.

### DE-126: Santen Pharmaceuticals

DE-126 is a prostaglandin eye drop drug product with a novel, mode of action that is both FP and EP3 receptors dual agonist. DE-126 is expected to show a superior intraocular pressure lowering effect compared to tafluprost, an FP receptor agonist. Santen Pharmaceutical initiated the enrolment in a phase II trial for Open angle

glaucoma and Ocular hypertension in USA.

Further product details are provided in the report.....

### Primary Open Angle Glaucoma: Therapeutic Assessment

This segment of the report provides insights about the different Primary Open Angle Glaucoma drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players in Primary Open Angle Glaucoma

There are approx. 10+ key companies which are developing the therapies for Primary Open Angle Glaucoma. The companies which have their Primary Open Angle Glaucoma drug candidates in the most advanced stage, i.e. phase III include Laboratorios Sophia S.A de C.V.

### Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

### Route of Administration

Primary Open Angle Glaucoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

### Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

### Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Primary Open Angle Glaucoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Open Angle Glaucoma therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Open Angle Glaucoma drugs.

## Primary Open Angle Glaucoma Report Insights

Primary Open Angle Glaucoma Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Primary Open Angle Glaucoma Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Primary Open Angle Glaucoma drugs?

How many Primary Open Angle Glaucoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Open Angle Glaucoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary Open Angle Glaucoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Primary Open Angle Glaucoma and their status?

What are the key designations that have been granted to the emerging drugs?

## Contents

Introduction

Executive Summary

Primary Open Angle Glaucoma: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Primary Open Angle Glaucoma – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Primary Open Angle Glaucoma companies' collaborations, Licensing, Acquisition  
-Deal Value Trends

Primary Open Angle Glaucoma Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

PRO-122: Laboratorios Sophia S.A de C.V.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

DE-126: Santen Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

WB-007: Whitecap Biosciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical Stage Products

Comparative Analysis

Drug Name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Primary Open Angle Glaucoma Key Companies

Primary Open Angle Glaucoma Key Products

Primary Open Angle Glaucoma- Unmet Needs

Primary Open Angle Glaucoma- Market Drivers and Barriers

Primary Open Angle Glaucoma- Future Perspectives and Conclusion

Primary Open Angle Glaucoma Analyst Views

Primary Open Angle Glaucoma Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Primary Open Angle Glaucoma

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Primary Open Angle Glaucoma

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Primary Open Angle Glaucoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PF2EF4EEC999EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PF2EF4EEC999EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970